No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ARWR240719P28000
- 0.10
- -0.90-90.00%
15min DelayClose Jul 19 15:59 ET
0.40High0.10Low
0.40Open1.00Pre Close110 Volume29 Open Interest28.00Strike Price2.60KTurnover546.30%IV1.41%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.2881Delta0.6213Gamma283.00Leverage Ratio-20.7097Theta0.0000Rho-81.54Eff Leverage0.0003Vega
Intraday
- 5D
- Daily
News
Analysts' Opinions Are Mixed on These Healthcare Stocks: CSL (OtherCMXHF) and Arrowhead Pharmaceuticals (ARWR)
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $54
BofA Securities analyst Jason Gerberry maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62
Piper Sandler analyst Edward Tenthoff maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and maintains the target price at $62.According to TipRanks data, the analyst has a success
TD Cowen Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Veeva Systems (VEEV) and Arrowhead Pharmaceuticals (ARWR)